 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Restas |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral, Intravenous |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 80-90% |
| Metabolism | Hepatic |
| Eliminationhalf-life | 60-90 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H16ClFN2O |
| Molar mass | 342.80 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Flutoprazepam (Restas) is a drug which is abenzodiazepine. It was patented in Japan by Sumitomo in 1972[1] and its medical use remains mostly confined to that country. Itsmuscle relaxant properties are approximately equivalent to those ofdiazepam - however, it has more powerfulsedative,hypnotic,anxiolytic andanticonvulsant effects and is around four times more potent by weight compared to diazepam.[2] It is longer acting than diazepam due to its long-acting active metabolites,[3] which contribute significantly to its effects.[4] Its principal active metabolite is n-desalkylflurazepam, also known as norflurazepam, which is also a principal metabolite offlurazepam (trade name Dalmadorm/Dalmane).[5][6]
Flutoprazepam is typically used for the treatment of severeinsomnia and may also be used for treatingstomach ulcers.[7]
Flutoprazepam does not fall under the internationalConvention on Psychotropic Substances of 1971, and is currently unscheduled in the United States.[8]
